» Articles » PMID: 28219993

Low Prevalence of Substandard and Falsified Antimalarial and Antibiotic Medicines in Public and Faith-Based Health Facilities of Southern Malawi

Overview
Specialty Tropical Medicine
Date 2017 Feb 22
PMID 28219993
Citations 27
Authors
Affiliations
Soon will be listed here.
Abstract

AbstractSubstandard and falsified antimalarial and antibiotic medicines represent a serious problem for public health, especially in low- and middle-income countries. However, information on the prevalence of poor-quality medicines is limited. In the present study, samples of six antimalarial and six antibiotic medicines were collected from 31 health facilities and drug outlets in southern Malawi. Random sampling was used in the selection of health facilities. For sample collection, an overt approach was used in licensed facilities, and a mystery shopper approach in nonlicensed outlets. One hundred and fifty-five samples were analyzed by visual and physical examination and by rapid prescreening tests, that is, disintegration testing and thin-layer chromatography using the GPHF-Minilab. Fifty-six of the samples were analyzed according to pharmacopeial monographs in a World Health Organization-prequalified quality control laboratory. Seven out-of-specification medicines were identified. One sample was classified as falsified, lacking the declared active ingredients, and containing other active ingredients instead. Three samples were classified as substandard with extreme deviations from the pharmacopeial standards, and three further samples as substandard with nonextreme deviations. Of the substandard medicines, three failed in dissolution testing, two in the assay for the content of the active pharmaceutical ingredient, and one failed in both dissolution testing and assay. Six of the seven out-of-specification medicines were from private facilities. Only one out-of-specification medicine was found within the samples from public and faith-based health facilities. Although the observed presence of substandard and falsified medicines in Malawi requires action, their low prevalence in public and faith-based health facilities is encouraging.

Citing Articles

Relationship between Prices and Quality of Essential Medicines from Different Manufacturers Collected in Cameroon, the Democratic Republic of the Congo, and Nigeria.

Gabel J, Martus P, Heide L Am J Trop Med Hyg. 2024; 111(6):1378-1395.

PMID: 39378886 PMC: 11619510. DOI: 10.4269/ajtmh.24-0309.


Suspected poor-quality medicines in Kenya: a retrospective descriptive study of medicine quality-related complaints reports in Kenya's pharmacovigilance database.

Toroitich A, Armitage R, Tanna S BMC Public Health. 2024; 24(1):2561.

PMID: 39300437 PMC: 11414318. DOI: 10.1186/s12889-024-20036-4.


Quality of antiretroviral, antimalarial and antituberculosis medicines in Zambia: Findings of routine post-marketing surveillance.

Jere E, Munkombwe D, Mukosha M, Mudenda S, Kalungia A, Chabalenge B J Med Access. 2024; 8:27550834241266755.

PMID: 39071988 PMC: 11273717. DOI: 10.1177/27550834241266755.


Prevalence of substandard, falsified, unlicensed and unregistered medicine and its associated factors in Africa: a systematic review.

Mekonnen B, Getie Yizengaw M, Worku M J Pharm Policy Pract. 2024; 17(1):2375267.

PMID: 39015754 PMC: 11251437. DOI: 10.1080/20523211.2024.2375267.


Quality of Essential Medicines from Different Sources in Enugu and Anambra, Nigeria.

Gabel J, Lachele M, Sander K, Gnegel G, Sunny-Abarikwu N, Ohazulike R Am J Trop Med Hyg. 2024; 111(1):179-195.

PMID: 38740019 PMC: 11229646. DOI: 10.4269/ajtmh.23-0837.


References
1.
. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Fiftieth report. World Health Organ Tech Rep Ser. 2016; (996):1-358, back cover. View

2.
Nayyar G, Breman J, Herrington J . The global pandemic of falsified medicines: laboratory and field innovations and policy perspectives. Am J Trop Med Hyg. 2015; 92(6 Suppl):2-7. PMC: 4455081. DOI: 10.4269/ajtmh.15-0221. View

3.
Chikowe I, Osei-Safo D, Harrison J, Konadu D, Addae-Mensah I . Post-marketing surveillance of anti-malarial medicines used in Malawi. Malar J. 2015; 14:127. PMC: 4377194. DOI: 10.1186/s12936-015-0637-z. View

4.
Almuzaini T, Choonara I, Sammons H . Substandard and counterfeit medicines: a systematic review of the literature. BMJ Open. 2013; 3(8):e002923. PMC: 3752049. DOI: 10.1136/bmjopen-2013-002923. View

5.
Wirtz V, Hogerzeil H, Gray A, Bigdeli M, de Joncheere C, Ewen M . Essential medicines for universal health coverage. Lancet. 2016; 389(10067):403-476. PMC: 7159295. DOI: 10.1016/S0140-6736(16)31599-9. View